Skip to content
    Real-World Studies

    Venetoclax linked to higher febrile neutropenia event density in AML cohort

    Ren et alCancer medicine

    Venetoclax linked to higher febrile neutropenia event density in AML cohort
    In a single-center real-world study evaluating newly diagnosed, non-M3 acute myeloid leukemia (AML) treated between 2015 and 2024 (n = 358; venetoclax [VEN] = 156, non-VEN = 202), researchers assessed infection dynamics following 1:1 propensity-score matching across nine baseline covariates (115 patients per group). While VEN improves remission rates in AML, treatment-related infectious toxicity presents substantial clinical challenges.
    Matched analysis demonstrated that VEN-based regimens were associated with a significantly elevated febrile neutropenia event density compared to conventional therapy (IRR, 1.77; 95% CI, 1.33–2.36; p < 0.001; 16.40 vs. 9.27 per 1000 person-days). Infection profiles varied notably by anatomic site and pathogen category. First-event incidence for upper-respiratory and pulmonary infections was lower with VEN, whereas skin/soft-tissue and perianal sites demonstrated higher event density without an increase in overall patient-level incidence. In terms of microbiology, first events of bacterial and fungal infections were fewer with VEN, though overall event densities remained comparable to conventional therapy; conversely, viral infections occurred earlier and accrued a higher cumulative incidence. First-infection rates were lower in the VEN cohort across days 30, 60, and 90, converging with conventional regimens by day 120.
    Multivariable modeling in the pre-matching cohort identified higher hematopoietic cell transplantation-specific comorbidity index (HCT-CI 1–2 or ≥3 vs. 0) and elevated direct bilirubin (DBIL) as independent baseline predictors of microbiologically documented infection (MDI), while female sex correlated with lower risk. Clinically, MDIs occurring within the first 90 days—driven by bacterial and fungal pathogens—were associated with inferior progression-free survival at 100-day and 365-day landmarks, while early viral infections demonstrated no clear association with survival outcomes.

    Key Takeaways

    • Venetoclax-based therapy was associated with a significantly higher event density of febrile neutropenia compared with conventional regimens (IRR, 1.77; 95% CI, 1.33–2.36; p < 0.001; 16.40 vs. 9.27 per 1000 person-days).
    • Cumulative incidence of first infection was lower under venetoclax at days 30, 60, and 90 before converging by day 120, with viral infections occurring earlier and reaching a higher cumulative incidence.
    • Microbiologically documented infections occurring within 90 days—primarily bacterial and fungal—were associated with inferior progression-free survival at landmark analyses of 100 and 365 days.